(19)
(11) EP 4 770 653 A1

(12)

(43) Date of publication:
08.07.2026 Bulletin 2026/28

(21) Application number: 24861210.3

(22) Date of filing: 30.08.2024
(51) International Patent Classification (IPC): 
A61K 35/17(2025.01)
 A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 35/00; A61K 35/17; C07K 14/7051; A61K 38/00; C07K 2319/03
(86) International application number:
PCT/US2024/044834
(87) International publication number:
WO 2025/050020 (06.03.2025 Gazette 2025/10)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 30.08.2023 US 202363579799 P

(71) Applicant: MiNK Therapeutics, Inc.
New York, NY 10010 (US)

(72) Inventors:
  • CHANTZOURA, Eleni
    Longstation CB24 3BT (GB)
  • IBBETT, Paul
    Lexington, MA 02421 (US)
  • VAN DIJK, Marc
    Lexington, MA 02421 (US)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)

   


(54) NOVEL T CELL RECEPTORS THAT BIND TO PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA (PRAME) AND METHODS OF USE THEREOF